Literature DB >> 21301430

Something new under the skin.

Michael Eisenstein.   

Abstract

One-size-fits-all intravenous delivery of biologics may be giving way to alternate delivery routes that enable safer and more efficient drug administration. Michael Eisenstein reports.

Mesh：

Substances：

Year:  2011        PMID： 21301430     DOI： 10.1038/nbt.1768

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


  4 in total

1.  Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.

Authors:  Stephan Stilgenbauer; Thorsten Zenz; Dirk Winkler; Andreas Bühler; Richard F Schlenk; Silja Groner; Raymonde Busch; Manfred Hensel; Ulrich Dührsen; Jürgen Finke; Peter Dreger; Ulrich Jäger; Eva Lengfelder; Karin Hohloch; Ulrike Söling; Rudolf Schlag; Michael Kneba; Michael Hallek; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2009-07-13       Impact factor: 44.544

2.  In vitro transdermal delivery of therapeutic antibodies using maltose microneedles.

Authors:  Guohua Li; Advait Badkar; Sandeep Nema; Chandra Sekhar Kolli; Ajay K Banga
Journal:  Int J Pharm       Date:  2008-10-19       Impact factor: 5.875

3.  Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.

Authors:  A Cortelezzi; M C Pasquini; A Gardellini; U Gianelli; A Bossi; G Reda; B Sarina; P Musto; W Barcellini; A Neri; G L Deliliers
Journal:  Leukemia       Date:  2009-07-30       Impact factor: 11.528

4.  Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer.

Authors:  Michael Ottiger; Michael A Thiel; Ulrich Feige; Peter Lichtlen; David M Urech
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-29       Impact factor: 4.799
  4 in total
  6 in total

Review 1.  Polymeric microneedles for transdermal protein delivery.

Authors:  Yanqi Ye; Jicheng Yu; Di Wen; Anna R Kahkoska; Zhen Gu
Journal:  Adv Drug Deliv Rev       Date:  2018-01-31       Impact factor: 15.470

2.  Intranasal delivery to the brain.

Authors:  Robert I Henkin
Journal:  Nat Biotechnol       Date:  2011-06-07       Impact factor: 54.908

3.  In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability.

Authors:  Vikas K Sharma; Thomas W Patapoff; Bruce Kabakoff; Satyan Pai; Eric Hilario; Boyan Zhang; Charlene Li; Oleg Borisov; Robert F Kelley; Ilya Chorny; Joe Z Zhou; Ken A Dill; Trevor E Swartz
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

4.  Charge-mediated Fab-Fc interactions in an IgG1 antibody induce reversible self-association, cluster formation, and elevated viscosity.

Authors:  Jayant Arora; Yue Hu; Reza Esfandiary; Hasige A Sathish; Steven M Bishop; Sangeeta B Joshi; C Russell Middaugh; David B Volkin; David D Weis
Journal:  MAbs       Date:  2016-08-25       Impact factor: 5.857

5.  High-level secretion of recombinant monomeric murine and human single-chain Fv antibodies from Drosophila S2 cells.

Authors:  Allissia A Gilmartin; Benjamin Lamp; Till Rümenapf; Mats A A Persson; Félix A Rey; Thomas Krey
Journal:  Protein Eng Des Sel       Date:  2011-12-12       Impact factor: 1.650

6.  Evaluating the administration costs of biologic drugs: development of a cost algorithm.

Authors:  Ebenezer K Tetteh; Stephen Morris
Journal:  Health Econ Rev       Date:  2014-10-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.